Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2,Condition 3a,Condition 3b
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001898,renal vascular resistance,,,,9.2,mmHg/ml/min,0.4,1.1314,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99963,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 14 days),
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,6,,CMO:0001898,renal vascular resistance,,,,8.8,mmHg/ml/min,0.5,1.2247,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99964,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days)
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,16,,CMO:0001898,renal vascular resistance,,,,7.1,mmHg/ml/min,0.3,1.2,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99998,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 154 days),
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,16,,CMO:0001898,renal vascular resistance,,,,6.8,mmHg/ml/min,0.3,1.2,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99999,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days)
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.32,ml/min/100g,0.11,0.3111,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99953,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 14 days),
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.42,ml/min/100g,0.09,0.2205,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99954,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days)
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002782,renal plasma flow to body weight ratio,,,,3.15,ml/min/100g,0.13,0.52,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99993,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 154 days),
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002782,renal plasma flow to body weight ratio,,,,3.19,ml/min/100g,0.13,0.52,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99994,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days)
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",kidney plasma flow trait,,RS:0003240,MWF/ZtmRrrc,male,126 days,8,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.84,ml/min/100g,0.1379,0.39,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 60 days),100940,enalapril (50 mg/l) (for 60 days),,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",kidney plasma flow trait,,RS:0003240,MWF/ZtmRrrc,male,246 days,6,,CMO:0002782,renal plasma flow to body weight ratio,,,,1.71,ml/min/100g,0.0939,0.23,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 182 days),100942,enalapril (50 mg/l) (for 182 days),,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",glomerular filtration trait,,RS:0003240,MWF/ZtmRrrc,male,126 days,8,,CMO:0002943,renal filtration fraction,,,,0.21,,0.0212,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 60 days),100944,enalapril (50 mg/l) (for 60 days),,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",glomerular filtration trait,,RS:0003240,MWF/ZtmRrrc,male,246 days,6,,CMO:0002943,renal filtration fraction,,,,0.3,,0.0163,0.04,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 182 days),100946,enalapril (50 mg/l) (for 182 days),,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",kidney plasma flow trait,,RS:0003240,MWF/ZtmRrrc,male,126 days,8,,CMO:0003684,renal plasma flow (PAH),,,,10.6,ml/min,0.5657,1.6,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 60 days),100936,enalapril (50 mg/l) (for 60 days),,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",kidney plasma flow trait,,RS:0003240,MWF/ZtmRrrc,male,246 days,6,,CMO:0003684,renal plasma flow (PAH),,,,7.6,ml/min,0.3266,0.8,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 182 days),100938,enalapril (50 mg/l) (for 182 days),,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood molecular composition trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002985,efferent arteriolar hydraulic pressure,,pt,,24,mmHg,0.4,1.1314,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,enalapril (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,109969,enalapril (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,